NYSE:ENOVMedical Equipment
Enovis Weighs US$501.3m Impairment Against Nebula Led Organic Growth
Enovis (NYSE:ENOV) recorded a goodwill impairment charge of over $500 million in Q4 2025, tied to changes in its business mix and accounting assumptions.
The company reported strong organic growth in key segments in the same period, supported by new product launches.
Recently introduced products, including the Nebula Stem and OrthoDrive Impactor, are gaining traction, with Nebula competing directly against established peers.
For investors tracking Enovis, the combination of a large goodwill...